ReviewCurrent rheumatology reviews2026
Using Multi-Omics Methods to Understand Gouty Arthritis.
Review in Current rheumatology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A systems immunology perspective on gout pathogenesis and its precision-targeted treatment strategies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Gouty arthritis is a common arthritic disease caused by the deposition of monosodium urate crystals in the joints and the tissues around it. The main pathogenesis of gout is the inflammation caused by the deposition of monosodium urate crystals. Omics studies help us evaluate global changes in gout during recent years, but most studies used only a single omics approach to illustrate the mechanisms of gout. In this review, we review the genomics, transcriptomics, epigenetics, proteomics, and metabolomics of gout, observing that different genes, DNA methylation, miRNAs, LncRNAs, circRNAs, proteins, and metabolites are found between hyperuricemia, acute gout arthritis, and chronic gout arthritis, and some of them are associated with disease activity, prognosis or treatment, which help us broaden our understanding of the pathogenesis and provide important clues for valuable biomarkers. To our knowledge, this is the first study that combines all omics studies from genomics to metabolomics and may serve as a reference for future studies to identify the key underlying pathways in gout.
Indexed as
Identifiers
39812052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.